Physician profile
Michael M Mccarthy
NPI 1619061389
$866.62
in general payments reported to CMS, 2019-2025
16 companies · $207 in 2025
The $207 reported for 2025 was more than what a typical Pediatric Pulmonology provider received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.92 · 2020: $17.51 · 2022: $236 · 2023: $236 · 2024: $85.29 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $528.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $528.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $222.45 | 2023-2025 | |
| Chiesi USA, INC. | $175.87 | 2022 | |
| Electromed, INC. | $145.42 | 2023-2025 | Smartvest |
| Sanofi-Aventis U.S. LLC | $59.99 | 2022 | |
| Abbott Laboratories | $48.66 | 2023 | Freestyle Libre 3 |
| Baxter Healthcare | $48.55 | 2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Synclara Cough System |
| Glaxosmithkline, LLC. | $39.21 | 2023 | Nucala |
| Mylan Specialty L.P. | $24.04 | 2023 | Yupelri |
| Vertex Pharmaceuticals Incorporated | $21.05 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.35 | 2019 | |
| Allergan, INC. | $17.51 | 2020 | |
| Advanced Respiratory, INC | $16.45 | 2019 | |
| Gilead Sciences, INC. | $15.48 | 2019 | |
| Merck Sharp & Dohme LLC | $13.59 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mccarthy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.